Sonepcizumab
- Generic Name
- Sonepcizumab
- Drug Type
- Biotech
- CAS Number
- 1031360-18-5
- Unique Ingredient Identifier
- O4T5UXS4P2
- Background
A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis. S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1).
- Indication
Investigated for use/treatment in solid tumors.
A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Lpath, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01762033
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Florida Cancer Specialists, Inverness, Florida, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.